IFN-alpha 2b

IFN-alpha 2b Molekülinformation

Englischer Name	Interferon alpha-2	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	10	Target-Alias	IFNA2B，IFNA2C，LeIF A，Interferon alpha-2，IFN-alpha-2，IFNA2，Interferon Alpha 2，Alpha-2a Interferon，Interferon Alpha 2b，Interferon Alpha A，Interferon Alpha 2a，Interferon Alpha-A，IFN-AlphaA，IFNA2A，INFA2，IFNA
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Interferon alpha-2
Target-Alias	IFNA2B，IFNA2C，LeIF A，Interferon alpha-2，IFN-alpha-2，IFNA2，Interferon Alpha 2，Alpha-2a Interferon，Interferon Alpha 2b，Interferon Alpha A，Interferon Alpha 2a，Interferon Alpha-A，IFN-AlphaA，IFNA2A，INFA2，IFNA
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	10
Höchste Forschungs- und Entwicklungsphase	Approved

IFN-alpha 2b Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
Fc Tag (1)His Tag & Avi Tag (1)
Marker
Unconjugated (1)Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
IFB-H5253	Human	HEK293	Human IFN-alpha 2b Protein, Fc Tag (MALS verified)				In den Warenkorb legen
IFB-H82E3	Human	HEK293	Biotinylated Human IFN-alpha 2b Protein, His,Avitag™ (MALS verified)				In den Warenkorb legen

Gesamtmenge2

IFN-alpha 2b Molekülhintergrund

IFN-alpha is a cytokine that has an immunomodulatory function. It plays an important role not only in antiviral activity but also in several physiologic functions, such as activation of dendritic cells and accelerated expression of major histocompatibility complex I and II molecules that may cause increased antigen presentation. Variants of human leukocyte interferon alpha 2 (IFN-alpha 2a, alpha 2b, and alpha 2c) differ from each other by changes in their coding regions at nucleotide positions 137 and 170. IFN-alpha 2b (IFNα-2b) is an important cytokine and used for antiviral and anticancer treatment.

IFN-alpha 2b Molekülalias

IFN-alpha 2b,IFNA2B,IFN-alpha 2 (alpha 2b),interferon alpha 2b

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science)		Phase 2 Clinical	Genenta Science Srl	Carcinoma, Renal Cell; Glioblastoma; Multiple Myeloma	Details
NG-641	EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP	Phase 1 Clinical	Akamis Bio Ltd	Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Squamous Cell Carcinoma of Head and Neck	Details
recombinant human serum albumin-interferon-alpha-2a fusion protein (Qilu Pharmaceutical)		Phase 1 Clinical	Qilu Pharmaceutical Co Ltd	Hepatitis B	Details
Q101-pegylated interferon alfa-2a (CSPC Zhongqi Pharmaceutical Technology)		Phase 1 Clinical	CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd	Hepatitis B, Chronic	Details
PEGylated interferon alpha-1b (Shanghai Institute of Biological Products)		Phase 1 Clinical	Shanghai Institute of Biological Products Co Ltd	Hepatitis B; Neoplasms; Varicella Zoster Virus Infection	Details
SFR-1882	SFR-1882	Phase 1 Clinical	Tianjin Sinobiotech Ltd	Anemia; Renal Insufficiency	Details
CX-801	CX-801	Phase 1 Clinical	Cytomx Therapeutics Inc	Carcinoma, Renal Cell; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
ORB-011	ORB-011	Phase 1 Clinical		Neoplasms; Solid tumours	Details
interferon alfa-2b follow-on biologic (Amoytop)		Clinical	Xiamen Amoytop Biotech Co Ltd	Condylomata Acuminata; Hepatitis B; Hepatitis C; Leukemia, Hairy Cell; Lymphoma, Follicular; Melanoma; Sarcoma, Kaposi	Details
interferon-alpha2b (The University Health Network)		Clinical	University Health Network (Uhn)	Coronavirus Disease 2019 (COVID-19)	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Nadofaragene firadenovec	SCH-721015; FE-999326; SCH-209702/SCH-721015; SCH-721015/SCH-209702; TR-002	Approved	Fkd Therapies, Schering-Plough Labo Nv	Instiladrin, Adstiladrin	United States	Urinary Bladder Neoplasms	Ferring Pharmaceuticals A/S	2022-12-16	Adenocarcinoma; Carcinoma, Transitional Cell; Mesothelioma; Pancreatic Neoplasms; Solid tumours; Urinary Bladder Neoplasms	Details